Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys and Entecavir in HBeAg Positive CHB
NCT00940485Phase 4Completed
- Sponsor
- Roche
- Start
- Apr 2009
- Primary completion
- Dec 2011
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Hepatitis B Envelope Antigen Seroconversion at Week 48. Started Apr 2009; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00940485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940485.